Blockchain Registration Transaction Record

NeuroOne Restates Q2 Results, Reaffirms FY2026 Revenue Guidance

NeuroOne Medical Technologies restates Q2 2026 results due to revenue overstatement of $0.5M, but reaffirms FY2026 revenue guidance of at least $10.5M. CEO Dave Rosa emphasizes one-time correction.

This news matters because it demonstrates NeuroOne's transparency in correcting a financial error while maintaining its revenue forecast, which is crucial for investor confidence in the medtech sector. For patients and healthcare providers, the restatement does not affect the company's ongoing operations or product development, including its innovative electrode and ablation systems that aim to improve surgical outcomes for neurological disorders. It underscores the importance of strong internal controls in high-growth companies.